Apellis Pharmaceuticals has slashed its headcount by a quarter and culled its pipeline to save $300m, which will be put towards supporting the ongoing launch of its potential blockbuster eye therapy, Syfovre.
Apellis Slashes Costs To Focus On Troubled Syfovre Launch
Cuts To Jobs And Pipeline
The blockbuster-tipped eye therapy Syfovre has hit safety doubts and Apellis is streamlining to give more support to the drug’s global launch.
More from Strategy
More from Business
• By
The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.
• By
Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.
• By
Deal Snapshot: Sanofi obtained global rights to a pair of bispecific antibody candidates for autoimmune and inflammatory bowel disorders from Helixon-affiliated AI firm Earendil.